Editas Medicine (EDIT) PT Raised to $15 at Credit Suisse
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rises after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts EDIT Hot Sheet
Price: $2.72 +4.62%
Rating Summary:
13 Buy, 12 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Rating Summary:
13 Buy, 12 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Join SI Premium – FREE
Credit Suisse analyst Richard Law raised the price target on Editas Medicine (NASDAQ: EDIT) to $15.00 (from $13.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Insulet Corporation (PODD) PT Raised to $163 at TD Cowen
- Datadog (DDOG) PT Lowered to $285 at Rosenblatt
- Flutter Entertainment (FLUT) PT Lowered to $160 at Jefferies
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
